MPiN
MPiN is a KV1.3 potassium channel inhibitor. The IC50 values of MPiN for inhibiting Kv1.3 currents are 1.1 μM (at -90 mV) and 0.6 μM (at -35 mV). MPiN exhibits in vivo efficacy in a mouse psoriasis model. MPiN can be used for the research of psoriasis.
For research use only. We do not sell to patients.
- CAS No.: 108975-37-7
- Formula: C17H21NO
- Molecular Weight:255.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
1.1 μM
|
Inhibition of human KV1.3 channel currents in HEK293T cells held at -90 mV (predominantly closed state) assessed via whole-cell patch-clamp electrophysiology assay with acute perfusion of MPiN.
Inhibition of human KV1.3 channel currents in HEK293T cells held at -90 mV (predominantly closed state) assessed via whole-cell patch-clamp electrophysiology assay with acute perfusion of MPiN.
|
2026.07.06.736759 |
| HEK-293T | IC50 |
0.6 μM
|
Inhibition of human KV1.3 channel currents in HEK293T cells held at -35 mV (predominantly inactivated state) assessed via whole-cell patch-clamp electrophysiology assay with acute perfusion of MPiN.
Inhibition of human KV1.3 channel currents in HEK293T cells held at -35 mV (predominantly inactivated state) assessed via whole-cell patch-clamp electrophysiology assay with acute perfusion of MPiN.
|
2026.07.06.736759 |
In Vitro
MPiN (10 μM) potently and reversibly inhibits human KV1.3 channels expressed in HEK293T cells, with higher inhibitory potency for inactivated channels (IC50 = 0.6 μM) than for closed channels (IC50 = 1.1 μM)[1].
MPiN (10 μM; 5 min) selectively inhibits human KV1.3 channels expressed in HEK293T cells, and acts only after the channels open[1].
MPiN (5-20 μM) allosterically promotes voltage sensor activation of human KV1.3 channels expressed in HEK293T cells, while inhibiting channel currents and inducing a hyperpolarizing shift in the activation curve without altering steady-state inactivation[1].
MPiN binds to a novel extracellular pocket formed by the PP1-PP2 turret loop, pore helix, and outer S5/S6 helices on human KV1.3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 5-6 weeks old, imiquimod-induced psoriasis model)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; once daily for 10 days
-
Result:Significantly reduced total Psoriasis Area and Severity Index scores.
Reduced spleen index.
Suppressed serum TNF-α levels.
Attenuated epidermal thickening.
Chemical Information
-
CAS No. 108975-37-7
-
Molecular Weight 255.35
-
Formula C17H21NO
-
SMILES
OC1=C(CN2CCCCC2C)C3=CC=CC=C3C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)